| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD1d |
| Uniprot No | P15813 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-335aa |
| 氨基酸序列 | MGCLLFLLLWALLQAWGSAEVPQRLFPLRCLQISSFANSSWTRTDGLAWL GELQTHSWSNDSDTVRSLKPWSQGTFSDQQWETLQHIFRVYRSSFTRDVK EFAKMLRLSYPLELQVSAGCEVHPGNASNNFFHVAFQGKDILSFQGTSWE PTQEAPLWVNLAIQVLNQDKWTRETVQWLLNGTCPQFVSGLLESGKSELK KQVKPKAWLSRGPSPGPGRLLLVCHVSGFYPKPVWVKWMRGEQEQQGTQP GDILPNADETWYLRATLDVVAGEAAGLSCRVKHSSLEGQDIVLYWGGSYT SMGLIALAVLACLLFLLIVGFTSRFKRQTSYQGVL |
| 预测分子量 | 63 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD1d重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*CD1d structure and lipid antigen presentation*
**作者**：Bendelac, A., Savage, P.B., Teyton, L.
**摘要**：该研究通过X射线晶体学解析了重组CD1d蛋白的分子结构，揭示了其脂质结合口袋的独特构象，并阐明了其如何结合和递呈脂类抗原(如α-半乳糖神经酰胺)给iNKT细胞，为设计靶向CD1d的免疫疗法奠定基础。
---
2. **文献名称**：*Recombinant CD1d–glycolipid tetramers for studying invariant NKT cell activation*
**作者**：Salio, M., Speak, A.O., Shepherd, D.
**摘要**：研究利用重组CD1d蛋白与荧光标记技术构建了CD1d-抗原四聚体，用于特异性检测iNKT细胞的抗原识别。该方法优化了重组CD1d在哺乳动物细胞中的表达，并验证了其在体外和体内模型中激活iNKT细胞的功能。
---
3. **文献名称**：*Expression and functional analysis of recombinant CD1d molecules in bacteria*
**作者**：Brennan, P.J., Tatituri, R.V., Brigl, M.
**摘要**：该研究开发了一种在大肠杆菌中高效表达重组CD1d蛋白的方法，并通过体外复性获得功能性蛋白。实验证明，重组CD1d能有效结合脂质抗原并激活iNKT细胞，为大规模生产CD1d用于免疫学研究提供了技术方案。
---
**备注**：以上文献均聚焦于CD1d重组蛋白的结构解析、表达优化及免疫学应用，覆盖了基础机制到技术开发的研究方向。如需具体期刊信息和发表年份，可进一步补充关键词检索。
CD1d is a non-classical major histocompatibility complex (MHC) class I-like protein that plays a critical role in lipid antigen presentation to natural killer T (NKT) cells, a unique subset of T lymphocytes bridging innate and adaptive immunity. Unlike MHC class I molecules that present peptide antigens, CD1d is specialized in binding and presenting lipid-based antigens, such as glycolipids, to invariant NKT (iNKT) cells via their semi-invariant T-cell receptors (TCRs). This interaction triggers rapid cytokine secretion and modulates immune responses in infections, cancer, and autoimmune diseases.
Recombinant CD1d proteins are engineered using expression systems (e.g., mammalian, insect, or bacterial cells) to produce soluble, functional forms of the protein for research and therapeutic applications. Structurally, CD1d consists of an α-heavy chain non-covalently associated with β2-microglobulin (β2m), forming a hydrophobic antigen-binding groove. Recombinant versions often include modifications like fusion tags (e.g., Fc or His-tags) to facilitate purification, detection, or stability.
These proteins are pivotal in studying CD1d-lipid antigen interactions, NKT cell activation mechanisms, and lipid-mediated immune regulation. For example, α-galactosylceramide (α-GalCer), a prototypical glycolipid antigen presented by CD1d, is used to explore iNKT cell responses in cancer immunotherapy. Recombinant CD1d tetramers loaded with lipid antigens enable the detection and isolation of antigen-specific NKT cells, advancing immunological assays.
Challenges in CD1d recombinant production include maintaining proper folding, lipid-loading efficiency, and structural integrity. Recent advances in protein engineering and structural biology (e.g., crystallography, cryo-EM) have improved our understanding of CD1d-lipid-TCR interactions, guiding the design of lipid-based vaccines or immunotherapies targeting NKT cells. Overall, recombinant CD1d proteins serve as essential tools for dissecting lipid-specific immunity and developing CD1d-targeted therapeutic strategies.
×
